Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore

M Premikha; Calvin J Chiew; Wycliffe E Wei; Yee Sin Leo; Benjamin Ong; David Chien Lye; Vernon J Lee; Kelvin Bryan Tan

doi:10.1093/cid/ciac288

Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore

Clin Infect Dis. 2022 Oct 12;75(8):1442-1445. doi: 10.1093/cid/ciac288.

Authors

M Premikha¹, Calvin J Chiew¹, Wycliffe E Wei¹, Yee Sin Leo^{2

3

4

5

6}, Benjamin Ong^{1

4}, David Chien Lye^{2

3

4

5}, Vernon J Lee^{1

6}, Kelvin Bryan Tan^{1

6}

Affiliations

¹ Ministry of Health, Singapore.
² National Centre for Infectious Diseases, Singapore.
³ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
⁴ Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
⁵ Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore.
⁶ Saw Swee Hock School of Public Health, National University of Singapore, Singapore.

Abstract

Compared with individuals vaccinated with Pfizer-BioNTech/Comirnaty, recipients of Sinovac-CoronaVac and Sinopharm were 2.37 (95% CI, 2.29-2.46) and 1.62 (95% CI, 1.43-1.85) times more likely to be infected with coronavirus disease 19, respectively, while individuals vaccinated with Moderna were 0.42 (95% CI, 0.25-0.70) times less likely to develop severe disease.

Keywords: COVID-19; SARS-CoV-2; inactivated vaccine; mRNA vaccine; vaccines.

MeSH terms

COVID-19 Vaccines
COVID-19* / prevention & control
Humans
RNA, Messenger
Singapore / epidemiology
Vaccines, Inactivated

Substances

COVID-19 Vaccines
RNA, Messenger
Vaccines, Inactivated